Rate My Professor Aurora Cruz-Cabeza

Her research centers on molecular crystals and crystallisation, encompassing polymorphism, mechanochemistry, crystal growth, pharmaceutical solvates, and solid-state transformations relevant to pharmaceuticals and agrochemicals. She collaborates extensively with industry partners, including AstraZeneca, to improve drug delivery through crystal engineering. Key publications include 'Phase diagrams of pharmaceutical solvates from mechanochemistry' in Nature Communications (2026, with F. Theodosiou et al.), 'When Reality Defies Prediction: Polymorphism, Twinning, and Accordion Crystals' in the Journal of the American Chemical Society (2026, with A. V. Hall et al.), 'Crystal size, shape, and conformational changes drive both the disappearance and reappearance of ritonavir polymorphs in the mill' in PNAS (2024, with P. Sacchi et al.), and 'Simple Quantification of Sticking Propensities of Pharmaceuticals with Mechanochemistry' in Molecular Pharmaceutics (2025, with M. Brocca et al.). With nearly 100 peer-reviewed papers and over 80 invited lectures worldwide, she has earned awards such as the 2023 BCA Prize Lecture. She leads the £7 million Molecular Solid Solutions (MoSS) project to revolutionize crystalline-based products in medicines and agrochemicals.